Mereo BioPharma Group plc Result of AGM (8157C)

TIDMMPH

RNS Number : 8157C

Mereo BioPharma Group plc

20 June 2019

Mereo BioPharma Group plc

("Mereo" or the "Company" or the "Group")

Results of Annual General Meeting

London and Redwood City, Calif., June 20, 2019 - Mereo BioPharma Group plc (AIM: MPH, NASDAQ: MREO), a clinical stage biopharmaceutical company focused on rare diseases, announces that all resolutions proposed at the Annual General Meeting, held yesterday, were duly passed. The Board is pleased that all the resolutions received strong support from shareholders and reports that Resolutions 1 to 6 passed as ordinary resolutions and Resolution 7 was passed as a special resolution.

About Mereo

Mereo is a biopharmaceutical company focused on the development and commercialization of innovative therapeutics that aim to improve outcomes for patients with rare diseases. Mereo's strategy is to selectively acquire product candidates for rare diseases that have already received significant investment from pharmaceutical and large biotechnology companies and that have substantial preclinical, clinical and manufacturing data packages. Mereo's existing portfolio consists of six clinical stage product candidates.

-- Setrusumab for osteogenesis imperfecta (OI). In October 2018, the Company announced completion of enrollment of 112 adult patients in a Phase 2b dose ranging study with initial positive 6-month open label data announced in May 2019 and top-line 12-month blinded dose ranging data expected in Q4 2019. A pediatric Phase 3 study design has also been approved by the EMA. Setrusumab has orphan designation in the U.S. and the EU and has been accepted into the PRIME and Adaptive Pathways in EU;

   --     Alvelestat for alpha-1 antitrypsin deficiency (AATD). The Company has initiated a Phase 2 proof-of-concept clinical trial in patients with severe AATD in the United States and the EU and expects to report top-line data from this trial at or about the end of 2019; 

-- Acumapimod for severe exacerbations of COPD. The Company announced positive Phase 2 data in May 2018 and recently announced the outline of the pivotal Phase 3 study including the primary and key secondary endpoints following the successful end of Phase 2 Type B meeting with the FDA;

-- Leflutrozole for hypogonadotropic hypogonadism (HH). The Company announced positive top-line Phase 2b data in March 2018 and positive results from the Phase 2b safety extension study in December 2018;

-- Navicixizumab has completed a Phase 1a single-agent clinical trial in patients with advanced solid tumors and is currently in a Phase 1b trial in combination with a standard paclitaxel regimen in patients with platinum-resistant ovarian cancer. This study recently completed enrolment; and

-- Etigilimab has completed a single-agent Phase 1a trial in patients with advanced or metastatic solid tumors and the Phase 1b combination study with nivolumab has fully enrolled and is currently in the safety monitoring phase.

Further Enquiries

 
Mereo                                          [phone] 
Denise Scots-Knight, Chief Executive Officer 
Richard Jones, Chief Financial Officer 
 
Cantor Fitzgerald Europe (Nominated Adviser 
 and Joint Broker to Mereo)                    [phone] 
Phil Davies 
Will Goode 
 
RBC Capital Markets (Joint Broker to Mereo)    [phone] 
Rupert Walford 
Jamil Miah 
 
FTI Consulting (Public Relations Adviser to 
 Mereo) 
Simon Conway                                   [phone] 
Brett Pollard 
Ciara Martin 
 
Burns McClellan (US Public Relations Adviser   +01 (0) 212 213 
 to Mereo)                                      0006 
Lisa Burns 
Steve Klass 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

RAGCKCDDABKDOAD

(END) Dow Jones Newswires

June 20, 2019 02:00 ET (06:00 GMT)